Pegcetacoplan is under clinical development by Apellis Pharmaceuticals and currently in Phase III for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis). According to GlobalData, Phase III drugs for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pegcetacoplan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pegcetacoplan overview
Pegcetacoplan (Empaveli, Aspaveli) is a synthetic peptide acts as a complement inhibitor. It is formulated as injectable solution for subcutaneous route of administration. Empaveli is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.
Pegcetacoplan (APL-2) is under development for the treatment of post-transplant recurrence of C3G or IC-MPGN, transplant-associated thrombotic microangiopathy (TA-TMA), IgA nephropathy (Berger's disease), lupus nephritis, primary membranous nephropathy, or C3 glomerulopathy (Kidney Disease (Nephropathy)) includes C3 glomerulonephritis, paroxysmal nocturnal hemoglobinuria (PNH) or cold agglutinin disease(wAIHA). It is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer. It is administered subcutaneously as an infusion for PNH and intravitreally for AMD. It is a compstatin derivative and a long-acting small cyclic peptide that targets complement factor C3. It was also under development for the treatment of kidney transplant rejection, refractory myasthenia gravis and neuromyelitis optica, neovascular age-related macular degeneration (AMD).
It was also under development for the treatment of amyotrophic lateral sclerosis (ALS) and geographic atrophy, autoimmune hemolytic anemia.
Apellis Pharmaceuticals overview
Apellis Pharmaceuticals (Apellis) is a clinical-stage biopharmaceutical company that carries out discovery, development, and commercialization of novel therapeutic compounds. Its products are used in therapeutic areas including ophthalmology, rare diseases, and neurology. The company offers products such as include SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan) which target C3, the central protein in the complement cascade. Apellis also offers APL-3007 products. Its products are used in the treatment of geographic atrophy, a leading cause of blindness, and paroxysmal nocturnal hemoglobinuria, a rare blood disease. The company operates in the US, Canada, Australia, the UK and Switzerland. Apellis is headquartered in Waltham, Massachusetts, United States.
For a complete picture of Pegcetacoplan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
